Replies to post #117873 on Innovation Pharmaceuticals Inc (IPIX)

[iclight]

From the ASCO abstract:

http://cellceutix.com/wp-content/uploads/2014/06/A-phase-1-dose-escalation-safety-pharmacokinetic-pharmacodynamic-study-of-thioureidobutyronitrile-a-novel-p53-targeted-therapy-in-patients-with-advanced-solid-tumors..pdf
STATUS:
A total of 40 subjects have been enrolled to date, 34 have completed cohorts 0-9 (which is actually cohorts 1-10).

That leaves 6 that were not complete as of Feb 3 when the abstract was submitted. They were enrolled and the cycle takes 28 days.

That's:
2 9th cohorts
3 10th cohorts
1 11th cohort

We know the one 10th cohort was not complete and I even assumed the 2 9th cohorts were both ovarian (though there are 5 9th cohorts that are not ovarian) which leaves 1 more 9th cohort in ovarian.